SEC Form 4 · accession 0001193125-26-359588
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Zalevsky
Officer — Chief R&D Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 7:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 18, 2026 | S | 186 | $71.98 | D | 9,570 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.